Table 1

Baseline demographics of patients (FAS)

Group A (n=96)Group B (n=95)Group C (n=50)
Febuxostat dose increasing 10–40 mgFebuxostat 40 mg+colchicineFebuxostat 40 mg
Age, mean (SD)47.4 (10.5)47.6 (11.1)46.4 (12.7)
Height, mean (SD), cm171.0 (5.7)170.8 (5.8)169.8 (6.9)
Weight, mean (SD), kg77.3 (12.4)76.5 (11.7)76.8 (16.4)
BMI, mean (SD), kg/m226.4 (3.6)26.2 (3.5)26.5 (5.1)
Systolic blood pressure, mean (SD), mm Hg132.6 (14.4)132.8 (16.3)132.6 (17.6)
Diastolic blood pressure, mean (SD), mm Hg84.5 (12.0)84.3 (11.9)82.6 (14.0)
Any history of ≥2 gout flares, n (%)74 (77.1)70 (73.7)38 (76.0)
Prior urate-lowering therapy, n (%)31 (32.3)31 (32.6)16 (32.0)
eGFR at entry, mean (SD), mL/min/1.73 m275.8 (16.2)76.6 (13.7)76.8 (17.5)
Serum urate at entry, mean (SD), mg/dL8.67 (1.38)8.51 (1.19)8.57 (1.17)
Serum creatinine at entry, mean (SD), mg/dL0.90 (0.16)0.88 (0.14)0.89 (0.15)
With any comorbidity, n (%)51 (53.1)47 (49.5)29 (58.0)
  • BMI, body mass index; eGFR, estimated glomerular filtration rate; FAS, full analysis set.